Toxicological evaluation of pH-sensitive nanoparticles of curcumin: acute, sub-acute and genotoxicity studies

Prajakta Dandekar1, Rohit Dhumal, Ratnesh Jain

  • 1Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, NP Marg, Matunga, Mumbai 400 019, India.

Insights

Curcumin-loaded Eudragit S100 nanoparticles demonstrate safety for oral drug delivery. Toxicological evaluations confirm no adverse effects, supporting their therapeutic potential.

Area of Science:

  • Nanotoxicology
  • Polymeric Nanoparticles
  • Drug Delivery Systems

Background:

  • Nanotoxicology research is emerging, impacting regulatory policies for nano-drug delivery.
  • Establishing toxicological profiles is crucial for the human safety and therapeutic use of nanocarriers.

Purpose of the Study:

  • To establish the toxicological profile of curcumin-loaded Eudragit S100 polymeric nanoparticles.
  • To assess the safety of these nanoparticles for oral administration.

Main Methods:

  • Acute-toxicity study (up to 2000 mg/kg body weight of curcumin).
  • Sub-acute toxicity study (28 days) at therapeutic and double therapeutic doses.
  • Genotoxicity assays: in vivo Micronucleus, Chromosomal Aberration, and Comet assays.

Main Results:

  • The formulation showed no toxicity at 2000 mg/kg body weight in the acute study.
  • Prolonged administration (28 days) at therapeutic and double doses was safe.
  • Genotoxicity studies confirmed cellular safety at therapeutic and triple doses.

Conclusions:

  • Curcumin-loaded Eudragit S100 nanoparticles are safe for short-term oral administration.
  • The formulation is also safe for prolonged oral administration, supporting its therapeutic application.

Related Concept Videos

Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
Toxicokinetics: Overview01:21

Toxicokinetics: Overview

Studies that assess how a drug is absorbed, distributed, metabolized, and excreted (ADME) at toxic doses are termed toxicokinetics. Understanding toxicokinetics helps predict adverse drug reactions (ADRs) and manage toxicity in humans.Toxicokinetics differs from pharmacokinetics mainly in the dose levels studied, with toxicokinetics focusing on higher toxic doses. The kinetics at these levels can be non-linear due to altered physiological processes. Toxicodynamics examines the relationship...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Bioactivation and Tissue Toxicity01:25

Bioactivation and Tissue Toxicity

Bioactivation is a metabolic process that transforms less reactive substances into highly reactive metabolites, initiating tissue toxicity. This transformation can lead to various toxic effects, including carcinogenesis and teratogenesis. Reactive metabolites are classified into two main types: electrophiles and free radicals.Electrophiles are electron-deficient species and are produced primarily by the enzyme cytochrome P-450 during the metabolism of compounds containing carbon, nitrogen, or...